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Abstract
Background: The effects on cell signalling networks upon blockade of cytotoxic T lymphocyte-associated antigen-4 (CTLA4)
using the monoclonal antibody tremelimumab were studied in peripheral blood mononuclear cell (PBMC) samples from
patients with metastatic melanoma.
Methodology/Principal: Findings Intracellular flow cytometry was used to detect phosphorylated (p) signaling molecules
downstream of the T cell receptor (TCR) and cytokine receptors. PBMC from tremelimumab-treated patients were
characterized by increase in pp38, pSTAT1 and pSTAT3, and decrease in pLck, pERK1/2 and pSTAT5 levels. These changes
were noted in CD4 and CD8 T lymphocytes but also in CD14 monocytes. A divergent pattern of phosphorylation of Zap70,
LAT, Akt and STAT6 was noted in patients with or without an objective tumor response.
Conclusions/Significance: The administration of the CTLA4-blocking antibody tremelimumab to patients with metastatic
melanoma influences signaling networks downstream of the TCR and cytokine receptors both in T cells and monocytes. The
strong modulation of signaling networks in monocytes suggests that this cell subset may be involved in clinical responses
to CTLA4 blockade.
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Introduction
The cytotoxic T lymphocyte associated antigen 4 (CTLA4,
CD152) is an activation-induced immunoglobulin family receptor
expressed by T lymphocytes that provides a dominant negative
signaling upon binding to the costimulatory molecules CD80
(B7.1) and CD86 (B7.2), leading to T cell tolerance and anergy [1].
Expression of CTLA4 on T cells is tightly regulated. In naı ¨ve T
cells, surface CTLA4 expression is inhibited by rapid endocytosis
resulting from CTLA4 binding to AP50, a subunit of the clathrin
adaptor AP-2 protein [2]. Once a T cell is activated through the T
cell receptor (TCR), downstream TCR signaling through src
kinases results in tyrosine phosphorylation of CTLA4 and
uncoupling it from AP50, resulting in its surface expression with
a peak of 48 hours after activation. Because of its much higher
affinity for B7 costimulatory molecules, cell surface CTLA4
efficiently competes with the positive costimulatory receptor [1].
The engagement of CTLA4 results in decreased TCR signaling,
decreased interleukin 2 (IL-2) transcription [3], and cell cycle
arrest at the G1 to S transition [4,5]. The phenotype of CTLA4
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autoimmune infiltration of multiple organs within weeks after
birth, provides evidence of the critical role of CTLA4 in regulation
of immune responses [6,7]. In addition, CTLA4 has been detected
on the surface of monocytes, but its role is currently not fully
understood [8].
Tremelimumab (formerly CP-675,206) is a fully human IgG2
monoclonal antibody in clinical development for patients with
cancer [9]. Clinical trials using tremelimumab demonstrate that
this antibody can induce durable tumor regressions (up to 8 years
at this time) in 7 to 10% of patients with metastatic melanoma
[10,11]. The presence of activated cytotoxic T lymphocytes
(CTLs) against melanoma has been confirmed by serial analysis of
patient-derived tumor biopsies [12]. Grade 3 or 4 toxicities in the
range of 20–30% are mainly inflammatory or autoimmune in
nature, which are on-target effects after inhibiting CTLA4-
mediated self-tolerance [10,11]. The lack of survival advantage
in the early analysis of a phase III clinical trial comparing
tremelimumab with standard chemotherapy for metastatic mela-
noma highlights the importance of a better understanding of how
this antibody modulates the human immune system [13].
Therefore, we studied changes in signaling pathways downstream
of the TCR and cytokine receptors, two major signaling pathways
modulated by CTLA4 blockade [3,14,15], in PBMC from patients
treated with tremelimumab.
The inhibitory effect of triggering CTLA4 by costimulatory
molecules results in direct inhibition of signaling downstream of the
TCR/CD3 complex [3]. A direct association between CTLA4 with
CD3f leading to its dephosphorylation has been reported, resulting
in the inhibition of of the leukocyte-specific protein tyrosine kinase
(Lck), a member of the src family of tyrosine kinases responsible for
early downstream signaling from the TCR [3]. The inhibitory role
of CTLA4 on TCR signaling is evident when analyzing
lymphocytes from mice genetically deficient in CTLA4, which
demonstrate markedly increased phosphorylation of CD3f-chain-
associated protein kinase 70 (ZAP70), SHC, Fyn and Lck [14].
Further confirmatory evidence for the critical role of CTLA4 in
inhibiting downstream signaling from the TCR comes from studies
in humans with a polymorphism in the CTLA4 gene region known
asCT60(A/G),whichresultsinincreasedincidence ofautoimmune
diseases like type 1 diabetes, Graves disease and Addison’s disease
[16]. CD4
+ T cells from subjects with this polymorphism have
increased ability to phosphorylate downstream molecules upon
CD3 stimulation [17]. TCR/CD3 signaling and src kinase family
phosphorylation leads to the activation of Ras and further
downstream activation of the mitogen-activated protein kinase
family (MAPK), including the extracellular signal-regulated kinase
(ERK), the Jun N-terminal kinase (JNK) and the p38 MAPK, a
pathway that leads to T cell proliferation [18]. Its inhibition by
CTLA4 engagement on T cells results in a cell cycle arrest, with
inhibition at the G1 stage [4,5]. The cell cycle arrest induced by
CTLA4 is not universal, since this effect varies in different
lymphocyte subsets and is dependent on prior cognate antigen
exposure. The CTLA4-induced cell cycle arrest is particularly
evident in CD4
+ T cells upon secondary antigen exposure, as
demonstrated in studies comparing murine TCR transgenic cells
with or without CTLA4 expression [5]. Data on a role of CTLA4 in
limiting CD8
+ T cell proliferation is more controversial [19,20].
In addition, Ras signaling downstream of TCR/CD3 activates
phosphoinositide 3-kinases (PI3K) leading to the phosphorylation
of the serine/threonine kinases AKT, also known as protein
kinases B (PKB), a pathway important for cell survival [21]. Given
the antagonistic effects on TCR signaling, CTLA4 engagement
would be expected to inhibit this pathway, which has been
demonstrated by some groups [22,23]. However, CTLA4 is also
known to bind the phosphatases SHP-2 and PP2A, two inhibitors
of AKT [14,24]. In some experimental systems it has been shown
that ligation of CTLA4 activates PI3K and AKT, resulting in
inhibition of Bcl-2 apoptotic family members and increased cell
survival [25]. The significance of AKT activation and apoptosis
inhibition has been explained as CTLA4 inhibiting cell prolifer-
ation through the inhibition of MAPKs and at the same time
promoting cell survival through the activation of PI3K/AKT,
resulting in T cell anergy and tolerance without T cell death [25].
It is currently unknown if these opposing effects can be explained
by different assay systems or by analyzing different immune cell
subsets. Therefore, we reasoned that co-staining with surface
molecules to identify immune cell subsets at a single cell level and
to determine the effects on phosphorylated PI3K and AKT in
PBMC obtained from patients receiving a CTLA4 blocking
antibody, together with molecules involved in cell cycle (cyclin D1)
and apoptosis (bcl-2), may provide information on the effects of
CTLA4 blockade in humans.
The second network studied by us was signaling immediately
downstream of cytokine receptors through signal transducers and
activators of transcription (STAT). STATs are a family of
cytoplasmic transcription factors that intercede the signaling by
cytokines. Upon cytokine binding to their receptor, STATs are
activated by Janus kinases (JAK) through phosphorylation of
tyrosine residues resulting in dimerization and migration to the
nucleus to regulate gene expression. Our primary intent was to
determine if exposure to CTLA4 blockade resulted in altered
responsiveness to cytokine activation, since CTLA4 has been long
recognized to inhibit IL-2 transcription and to lower production of
immune activating cytokines [3]. In addition, evidence has been
provided for a potential direct interaction between CTLA4 and
STAT5 using a two-hybrid yeast system [15], although the
relevance of these findings to primary human T cells is currently
unknown. Furthermore, certain STATs can be additionally
phosphorylated by src protein kinases and MAPK kinases
[26,27], thereby being potential downstream effectors of TCR
and costimulatory activation. Therefore, we anticipated that
blockade of CTLA4 would result in a direct or indirect increase
in phosphorylated STAT proteins.
Work pioneered by Garry Nolan’s group has provided a
technique to allow the quantitative study of activated proteins
within cell signaling networks through multiparameter flow
cytometry, with simultaneous surface and intracellular staining
[28]. This technique, termed phosphoflow, is based on the use of
antibodies specific for intracellular phosphorylated proteins in
permeabilized cells [28,29]. Phosphoflow allows the study of cell
signaling pathways at a single cell level, with the benefit of allowing
a concomitant characterization of the cell type being studied using
polychromatic surface flow cytometry staining. Aided by this
technique, in the current work we explored the effects of the anti-
CTLA4 antibody tremelimumab on the phosphorylated state of
key effectors of the TCR and cytokine signaling pathways within
immune subsets of cells obtained from peripheral blood of patients
with metastatic melanoma. Our studies provide evidence of the
selective effects of blocking CTLA4 in humans at the cellular and
molecular level.
Materials and Methods
Clinical Trials and Study Samples
Peripheral blood samples were obtained after written informed
consent from 27 patients with stage IIIc or IV melanoma treated
at UCLA within two protocols based on the administration of
CTLA4 Blockade Phosphoflow
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approved by the UCLA Internal Review Board (IRB) with
approval numbers of 03-12-023, 04-07-063 and 06-06-093. These
approvals allowed the collection of PBMC after signing a written
informed consent and their analyses using the immune monitoring
assays described in this manuscript. Six patients were treated
within a phase I clinical trial of three biweekly intradermal (i.d.)
administrations of a fixed dose of 1610
7 autologous DC pulsed
with the MART-126–35 immunodominant peptide epitope
(MART-1/DC) manufactured as previously described [30],
concomitantly with the intravenous (i.v.) administration of a dose
escalation of tremelimumab at 10 (3 patients) and 15 mg/kg (3
other patients) every 3 months (UCLA IRB# 03-12-023, IND#
11579, clinical trial registration number NCT0090896). Samples
from these patients were coded with the study denomination of
NRA and a patient-specific number. The remaining 21 patients
were enrolled in a phase II clinical trial of single agent
tremelimumab (UCLA IRB# 06-06-093, IND# 100453, clinical
trial registration number NCT00471887) administered at 15 mg/kg
every 3 months. Samples from these patients were coded with the
study denomination of GA and a patient-specific number. Objective
clinical responses were recorded following a modified Response
Evaluation Criteria in Solid Tumors (RECIST) [31], where skin and
subcutaneous lesions evaluable only by physical exam were
considered measurable if adequately recorded using a photographic
camera with a measuring tape or ruler; there was no minimum size
restriction for these lesions. PBMC were obtained from two healthy
subjects by leukapheresis under UCLA IRB#04-07-063 and
discarded healthy donor PBMC were obtained from three
anonymized samples from the virology core at UCLA. These
PBMC were used to perform in vitro monocyte staining and anti-
CTLA4 antibody titration experiments.
Sample Procurement and Processing
PBMC were collected from patients receiving tremelimumab-
containing experimental immunotherapy by leukapheresis as
previously described [32]. Leukaphereses were planned as part of
the pre-dosing procedures, and between one and two months after
receiving the first dose of tremelimumab. Phosphoflow studies were
runusingaliquotsofcryopreserved PBMCthawedand immediately
diluted with RPMI complete media containing 5% human AB
serum and 1% penicillin, streptomycin, and amphotericin (Omega
Scientific, Tarzana, CA). Cells were washed and subjected to
enzymatic treatment with DNase (Sigma, St. Louis, MO) for 1 hour
at 37uC, and rested overnight in a 5% CO2 incubator.
Optimization of the Cell Surface Staining Protocol
We first optimized the conditions and antibody clones for
simultaneous cell surface and intracellular staining. We analyzed
the performance of commercially-available antibodies for cell
surface staining in fresh cells compared to cells fixed with 2%
paraformaldehyde (Electron Microscopy Services, Fort Washing-
ton, PA) and permeabilized using 90% ice-cold methanol. The
following antibodies were tested: phycoerytherin-Cy5 (PE-Cy5)-
CD3(UCHT1,BeckmanCoulter, Fullerton,CA),allophycocyanin-
Cy7 (APC-CY7)-CD4 (RPA-T4) and PE-CD8 (RPA-T8, BD
Biosciences); Pacific blue (PacBlue)-CD14 (Tu ¨K4) and PacBlue-
CD8 (clone 3B5, Invitrogen, Carlsbad, CA), PacBlue-CD8 (clone
OKT8, eBioscience, San Diego). For all flow cytometry experi-
ments, a combination of anti-mouse Igk/Negative Control
Compensation Particles (BD Biosciences) and PBMC were used
for compensation purposes. The fluorescent minus one (FMO)
approach was used to gate appropriately [32,33]. Samples were
acquired in a LSR II Flow Cytometer (BD Biosciences). All flow
data analysis was done with the FlowJo software (Tree Star Inc.,
Asland, OR), and plotted with GraphPad Prism (GraphPad, San
Diego, CA) for statistical analysis and graphing. We collected and
depicted the data using bi-exponential axis.
Cellular Barcoding, Surface Staining and Intracellular
Phospho-specific Flow Cytometry
Paraformaldehyde-fixed PBMC were washed twice in 3 ml of
phospho-staining buffer (Dulbecco phosphate buffer saline,
DPBS), 0.5% bovine serum albumin (BSA), and 0.01% sodium
azide. At the time of permeabilization with 90% ice-cold
methanol, post-dosing samples were labeled following the cellular
barcoding technique [34] with 5 and 6 mg/ml of Pacific orange-
succinimidyl ester (-NHS) and Ax350-NHS (Invitrogen, Carlsbad,
CA) respectively, and the pre-dosing samples were left unstained,
resulting in two barcoded samples that were then combined into
the same tube for both surface and intracellular staining. The
intracellular staining antibodies were used at saturating conditions
(see Table S1 for antibody clones, flurochrome labeling and
vendors). PBMC were stored at 220uC for up to three days until
flow cytometry analysis, as described [28,29,35].
Cytokine Stimulation Experiments
We first optimized the protocol to define the cytokine
concentration for maximal pSTAT detection using ten-point
dose-response curves of titrated concentrations of several human
cytokines in geometric series. The following cytokines were
titrated: interleukin 2 (IL-2, gift from Novartis, Emeryville, CA),
IL-4 (CellGenix, Freiburg, Germany); IL-6 and interferon-gamma
(IFN-c, BD Biosciences); IL-7 (eBioscience); IL-15 (gift from
Amgen, Thousand Oaks, CA); and interferon-alpha (IFN-a,
Chemicon/Millipore, Billerica, MA). Downstream TCR signaling
experiments were performed using media containing 300 IU/ml
of IL-2 and 50 ng/ml of OKT3 (eBioscience, San Diego,CA) at
different time points. PBMC and cytokines were incubated at
37uC, 5% CO2 for 15 minutes, and TCR signaling experiments
were done with a 30 minute incubation. PBMC were fixed in 2%
paraformaldehyde, permeabilized in 90% ice-cold methanol and
surface and intracellularly stained for flow cytometry as described
above.
Anti-CTLA4 Stimulation In Vitro Experiments
To obtain monocytes, thawed PBMC from one healthy subsject
and three patientswith metastaticmelanoma wereallowed to adhere
after overnight incubation. For the detection of CTLA4 expression
by monocytes, adherent PBMC were scraped and stained with anti-
CD3, anti-CD14 and anti-CTLA4 for CTLA4 surface stainig, or
surface stained with anti-CD3 and anti-CD14 before fixation and
permeabilization with iTAg fixative and permeabilization reagents
(Beckman Coulter), and then intracellularly stained with anti-
CTLA4-PE antibody. All antibodies used in these studies are
detailed in Table S2. For in vitro studies of anti-CTLA4 engagement
in monocytes, tremelimumab was added to the adherent PBMC at
titrated concentrations. After 2 days in culture, cells were fixed and
permeabilized for phosphoflow analysis as described above. During
the permeabilization time, samples underwent fluorescent cell
barcoding [34]. Briefly, samples were labeled with a combination
of 0, 3 or 8 mg/ml of Ax350-NHS and 0 or 3 mg/mlof Ax750-NHS,
or a combination 0 or 6 mg/ml of Ax350-NHS and 0 or 3 mg/ml of
Ax750-NHS. This approach allowed the simultaneous analysis of
four to six different populations in the same sample. Barcoded
monocyte samples were analyzed using a combination ofsurfaceand
intracellular staining antibodies detailed in Table S2.
CTLA4 Blockade Phosphoflow
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In all caseswecollectedone million CD3
+lymphocytes through flow
cytometry. Mean fluorescent intensity (MFI) was used as a measure of
pre- and post-treatment basal change. GraphPad Prism (GraphPad
Software, San Diego, CA) package program and Microsoft Excel were
used for data presentation. Two-tailed paired Student t-test was used to
compare pre- and post-treatment tremelimumab effects.
Results
Patient Characteristics and Sample Procurement
Cells collected from peripheral blood by leukapheresis from 27
patients enrolled in two clinical trials administering tremelimumab
were analyzed (Table 1). Six patients received tremelimumab together
with MART-126–35/DC (NRA study) and 21 patients received
tremelimumab alone (GA study). The majority of patients had M1c
metastatic melanoma (visceral metastasis and/or high LDH). Overall,
6 patients (4 in the GA study, 2 in the NRA study) had an objective
tumor response, resulting in sustained and durable tumor regressions
in 5 of them. These 6 patients had either stage IIIc or M1a metastatic
melanoma. Major toxicities included two cases of grade 3 diarrhea or
colitis and one case of symptomatic panhypopituitarism (grade 2
hypophysitis). None of these patients received corticosteroids or other
immune suppressive treatment before the post-dosing sample
collection for the phosphoflow analysis. Due to differences in clinical
trial design the post-dosing leukaphereses were performed at a median
of 38 days after the dose of tremelimumab in the GA cohort, and at a
median of 71 days in the NRA cohort. In both cases, serum levels of
tremelimumab were expected to be above 10 mg/ml at the time of
blood cell collection, a concentration of this antibody consistent with
CTLA4 blockade in vitro [9,10].
Phosphoflow Technique Optimization
We first established an optimized combination of antibodies
against cell surface and intracellular signaling molecules. Cell
permeabilization with the use of methanol had a significant
influence on the quality of both surface and intracellular staining.
Theexpression ofCD8aftercellpermeabilizationwasdetectedwith
only one of three antibodies tested (Figure S1). Additionally, in
preparation for cytokine stimulation studies, different cytokines at
increasing concentrations were tested to generate a sufficient dose-
response curve to obtain the highest phosphorylation signal after 15
minutes of cytokine stimulation. The optimal cytokine concentra-
tions were obtained following a geometric series determining a
plateau between cytokine concentration and maximum specific
phosphorylated protein detection (see Figure S2 and Table S3 for
optimization of the time-course for TCR stimulation experiments).
Simultaneous Analysis of Pre- and Post-dosing Samples
with Combined Surface and Intracellular Staining
We wanted to simultaneously analyze pre- and post-dosing
PBMC samples to minimize within-run analytical variability while
allowing detailed analysis for each major immune cell subset.
Therefore, a two cellular-barcoded approach was used in which
the post-dosing samples were labeled with Pacific orange-NHS
and combined with unlabeled predosing-samples, and both
populations were stained for the expression of surface and
intracellular molecules (Figure 1a). First, side and forward scatters
were used to determine cellular morphology followed by resolution
of the cellular barcoding into the two original populations (pre-
and post-dosing samples, Figure 1b). Then, the identification of
immune cell subsets was performed using a combination of CD3,
CD4 and CD14, where CD4
+ T helper cells were detected as
double positive CD3
+CD4
+ cells, CD8
+ CTLs as CD3
+CD4
2
and/or CD3
+CD8
+, and monocytes as CD3
2CD14
+ (Figure 1c).
The MFI of each phosphoprotein was measured for each
individual cell subset (Figure 1d).
Modulation of TCR and Cytokine Receptor Signaling After
Administration of Tremelimumab Together with
Dendritic Cell Vaccines
We first analyzed changes in phosphoprotein expression in post-
dosing samples from 6 patients treated within the NRA study
(combination of tremelimumab and MART-126–35/DC vaccines,
Figure 2). In the post-dosing population, phosphorylation of the
proximal src kinases pLAT (p,0.001) and pZAP70 (p,0.05)
decreased in CD8
+ (Figure 2b, c) but no changes were detected in
pLck or pAKT (Figure 2a, d). There was a significant increase in
pp38 in CD14
+ monocytes (p,0.001), with a similar but non-
significant trend in both T cell subpopulations (Figure 2e). Analysis
of whole protein levels of cyclin D1 (to explore cell cycle changes,
Figure 2g) and bcl-2 (to explore apoptotic molecule changes,
Figure 2h) did not demonstrate significant changes, other than a
small significant post-dosing decrease in bcl-2 protein only in
CD4
+ cells (p,0.05). Post-dosing levels of pSTAT1 and pSTAT3
increased consistently in all cell subsets, being statistically
significant in all cases except for pSTAT3 in CD4
+ cells
(p,0.05, Figure 2i, j). Post-dosing pSTAT5 and pSTAT6 were
not significantly different from pre-dosing values (Figure 2k, l).
T Cells and Monocytes Functionally Respond to Cytokine
Stimulation Without Differences Between Pre-dosing and
Post-dosing Samples
We then analyzed if in vivo exposure to tremelimumab would
enhance the ability of cells to respond to cytokine pulsing by
Table 1. Patient characteristics.
Patient cohort
NRA GA
Number of patients 6 21
Mean age (range) 56 (34–61) 52 (27–81)
Female/male 2/4 4/17
Stage IIIc 1 3
M1a 2 2
M1b 0 2
M1c 3 14
Prior therapy Surgery only 1 13
Immunotherapy only 3 3
Chemotherapy only 1 3
Immunotherapy and
chemotherapy
12
Tremelimumab dose 10 mg/kg q3 months 3 0
15 mg/kg q3 months 3 21
MART-1/DC 6 0
Toxicities Grade 2 pruritus 0 2
Grade 2 diarrhea 0 3
Grade 2 hypophysitis 0 1
Grade 3 colitis 0 2
Response Partial response 1 1
Complete response 1 3
doi:10.1371/journal.pone.0012711.t001
CTLA4 Blockade Phosphoflow
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STAT1 and STAT5, and pulsing with this cytokine led to a
consistent increase in pSTAT1 as expected (Figure S3). However,
there were no differences in pSTAT1 and pSTAT5 levels after
stimulation with IFN-c (data not shown). We also analyzed
pSTAT5 after pulsing with the common gamma-chain (cc)
signaling Th1 cytokines IL-2, IL-7 and IL-15. pSTAT5 increased
after cytokine stimulation, but there were no detectable changes
comparing pre- and post-tremelimumab treatment samples (Figure
S4). When stimulating cells with the Th2 cytokine IL-4, which also
signals through the common cc receptor, there were no differences
in pSTAT1 and pSTAT5, but there was a significant increase in
pSTAT6 in all three cell subsets. As with the other cytokines, there
were no differences in stimulated pre- and post-tremelimumab
treatment samples (data not shown). Taken together, treatment
with tremelimumab and MART-126–35/DC vaccines did not alter
the ability of T cells or monocytes to respond to cytokine
stimulation.
Detection of CTLA4 and Signaling Changes Upon CTLA4
Blockade in Monocytes
After repeatedly detecting changes in signaling phosphoproteins
in CD14
+ monocytes obtained from patients after treatment with
tremelimumab, we performed in vitro experiments with monocytes
from a healthy subject and three patients with metastatic to
confirm the expression of CTLA4 and the modulation of
phosphoproteins upon CTLA4 blockade. There was no significant
detection of surface CTLA4 on monocytes by flow cytometry
(0.1060.02%, 13 replicates, n=8 subjects) but we could readily
detect intracellular CTLA4 in monocytes (89.9361.40%, 30
replicates, n=8 subjects), with no difference in either staining
between a healthy subject and patients with melanoma (a
Figure 1. Outline of flow cytometry staining, cellular barcoding and phosphoflow analysis. a) Fixation, permeabilization, fluorescent
barcoding and surface and intracellular staining sequence for pre- and post-tremelimumab treatment samples. b) Gating pyramid. After gating by
morphology, pre- and post-dosing samples were resolved based on the Pacific orange barcoding cell labeling. c) The cells from pre- (negative for
Pacific orange) and post-treatment (positive for Pacific orange) time points were then separated as CD3
+ (T lymphocytes) and CD14
+ (monocytes).
The CD3
+ cells were gated on CD4
+ to analyze T helper cells, and CD4
2 cells to analyze for CD8
+ cytotoxic T lymphocytes (CTLs). d) Intracellular
phosphoproteins were analyzed in each cell subset by mean fluorescence intensity (MFI).
doi:10.1371/journal.pone.0012711.g001
CTLA4 Blockade Phosphoflow
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CTLA4 in monocytes is included in Figure S5a). After a 48-hour
incubation with tremelimumab in vitro the intracellular expression
of CTLA4 in monocytes decreased, demonstrating target
modulation even with undetectable surface expression of CTLA4
(Figure 3). Phosphorylation of Erk, STAT1, STAT3 and STAT6
did not change significantly with ex vivo tremelimumab exposure in
samples from five healthy donors and three patients with
metastatic melanoma, while intracellular pp38, and pAKT
decreased significantly from baseline with increasing concentra-
tions of tremelimumab only in samples from patients with
melanoma (Figure 3 and Figure S5). Phosphorylation of STAT5
decreased significantly with increasing concentrations of tremeli-
mumab in monocytes from five healthy donors and from three
patients with melanoma. Overall, these data demonstrate that
monocytes express mostly intracellular CTLA4 and that CTLA4 is
biologically active in this cell subset since exposure to tremelimu-
mab induces changes in intracellular signaling molecules.
Confirmation of the Modulation of TCR and Cytokine
Receptor Signaling After Administration of
Tremelimumab
Our most consistent effects in post-tremelimumab treatment
samples from the NRA study were changes in pp38, pLAT,
pZAP70, pSTAT1 and pSTAT3 in the absence of additional ex
vivo TCR or cytokine stimulation (Figure 2). These results were
based on the analysis of paired samples from only 6 patients, and
this study had the confounding effect of the administration of a
MART-126–35 peptide pulsed DC vaccine in addition to
Figure 2. Basal levels of TCR and cytokine signaling pathways in samples taken from patients in the NRA study of tremelimumab
administered together with MART-126–35 peptide pulsed dendritic cells (DC). The MFI of phosphoproteins was measured in CD3
+CD4
+ (T
helper), CD3
+CD4
2 (mainly representing CD8
+ CTLs) and CD3
2CD14
+ (monocyte) cell subsets. PBMC were obtained from patients before (Pre) and
after (Post) receiving the combined therapy. a) pLck (pY505), b) pZAP70 (pY292) and c) pLAT (pY171) representative of proximal T cell receptor (TCR)
activation, which was only analyzed in CD3 gates including CD4 and CD8 cells. d) pAKT (pT308), e) p38 (pT180/pY182), f) pERK1/2 (T202/204),
correspond to the main intracellular signaling pathways downstream of surface receptors, including the TCR. g) Cyclin D1 and h) bcl2 were measured
as whole protein content for surrogate evidence for modulation of the cell cycle and apoptosis, respectively. i) Phospho-STAT1 (pY701), j) pSTAT3
(pY705), k) pSTAT5 (Y694) and l) pSTAT6 (Y641) were studied as a measure of STAT signaling downstream of cytokine receptors. In all cases, p values
were calculated using a two-sided paired t-test, and significant results are denoted with a line comparing pre- and post-dosing samples with an
asterisk to represent the significance level as follows: *p , 0.05; **p , 0.01; ***p , 0.001. Y-axis= MFI - mean fluorescent intensity. Each dot
represents the average of six replicates in most instances, and twenty-four replicates for pSTAT 1 and pSTAT5. The horizontal bar in each scatter
column indicates medians. The vertical bar in each scatter column indicates standard error.
doi:10.1371/journal.pone.0012711.g002
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a validation set of samples taken from the GA study using paired
samples from 21 patients who received single agent tremelimumab
at 15 mg/kg every 3 months (Figure 4). In this larger dataset we
confirmed a statistically significant increase in pp38 for the three
cell subsets (CD4, CD8, CD14) in post-dosing samples. Surpris-
ingly, we detected decreases in pLck (statistically significant in all
cell subsets; p,0.001), and pERK1/2 (significant in CD8+ and
CD14+ cells, p,0.05), but no significant changes in pLat, pZap70
or pAkt. Analysis of phosphorylated STAT proteins (without
additional ex vivo cytokine stimulation) confirmed the increasing
trend in pSTAT1 and pSTAT3 in post-dosing samples, in both
cases statistically significant in the CD4
+ (p,0.05) and CD14
+
subsets (p,0.001). In addition, we also noted a consistent decrease
in pSTAT5 in post-dosing samples, which was statistically
significant in all three cell subsets (p,0.01).
Differential Phosphorylation Patterns in Patients with
Clinical Response to Tremelimumab
Finally, we explored if samples from patients with an objective
response to therapy had different patterns of changes in the
signaling pathways compared to patients without objective tumor
responses. This was done in the GA larger dataset, comparing
three patients with a durable complete response with 18 patients
with disease progression. Of note, there were no significant
differences in the mean time of the post-dosing leukapheresis
between patients with or without a clinical response. The general
trends of decrease in pLck, pErk1/2 and pSTAT5 and increase in
pp38, pSTAT1 and pSTAT3 continued to be evident both among
clinical responders and non-responders when analyzed in two
separate subgroups (data not shown). However, there were
divergent trends between these two groups of patients in terms
of pZap70, pAkt and pSTAT6 (Figure 5). Patients with a complete
clinical response to therapy had statistically significant decreases in
post-treatment pSTAT6 in all three cell subsets (p,0.05), while
patients without a clinical response had minimal changes or even a
trend towards increase in these two phosphorylated molecules
(Figure 5a to c). The same trend was evident for pAkt, with the
decrease in clinical responders only statistically significant in CD8
cells (p,0.05, Figure 5b). All three cell subsets showed an
increasing trend in pAkt in post-dosing in samples from the clinical
non-responders, which was significant for CD14
+ cells (p,0.05).
The proximal pZap70 showed a significant increase in CD8 cells
(p,0.01) in non-responders. Therefore, this exploratory analysis
suggests that patients with a clinical response to tremelimumab
may display different immune cell activation patterns in peripheral
blood.
Discussion
Enabled by the phosphoflow technique, which permitted the
concomitant multiparameter evaluation of surface and intracellu-
lar signaling patterns at a single cell level, we explored how the
anti-CTLA4 antibody tremelimumab altered cell signaling
pathways downstream of the TCR and cytokine receptors in
peripheral blood cells obtained from patients with metastatic
melanoma treated within two clinical trials. Phosphorylation was
used as readout for either a constitutive or stimulus-induced
pathway activation, thereby providing both phenotypic and
Figure 3. Modulation of CTLA4 and phosphoprotein expression in monocytes exposed ex vivo to tremelimumab. Monocytes were
cultured in increasing concentrations of tremelimumab for 48 hours, after which were analyzed for intracellular flow cytometry. Data is presented as
fold change from the baseline mean fluorescence intensity (MFI) at increasing concentrations of tremelimumab (0, 0.1, 1. 10. 15 and 100 mg/ml)
presented in a semilogarithmic plot. Red triangles represent monocytes samples obtained from three patients with metastatic melanoma (MD:
melanoma donors); black circles are results from monocytes analyzed from five healthy subjects (HD: healthy donors). a) Intracellular CTLA4
expression; b) pp38(pT180/pY182); c) pErk1/2 (T202/204); d) pAkt (pT308); e) pSTAT1(pY701); f) pSTAT3 (pY705); g) pSTAT5 (Y694); h) pSTAT6 (Y641).
**p , 0.01; ***p , 0.001.
doi:10.1371/journal.pone.0012711.g003
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tremelimumab-based therapy has a preferential effect on intracel-
lular signaling pathways mainly in CD4
+ and CD14
+ cells. CD4
+
T cell activation by anti-CTLA4 antibodies, detected as increase in
the surface marker HLA-DR, was the earliest described activation
effect of these antibodies on the human immune system
[32,36,37], which has been expanded to the detection of
activation-induced ICOS surface expression upon CTLA4
blockade [38,39]. However, there has not been much preclinical
or clinical data supporting an increased activation state of
monocytes, even though this cell subset has been previously
shown to expresses CTLA4 [8]. We noted a consistent increase in
phosphorylated p38, STAT1 and STAT3 in monocytes, with most
of these changes being highly significant in samples from both
clinical trials with tremelimumab. In our studies we confirmed the
expression of CTLA4 in monocytes, which was mostly intracel-
lular, with weak direct modulating effects of tremelimumab on
signaling phosphoprotein networks.
The most solid findings derived from the initial analysis of the
NRA combined therapy study were confirmed in the GA single
agent study, but results differed slightly. Differences in results
between both studies can be explained by several reasons. The
addition of MART-126–35/DC vaccines in the NRA study, which
was aimed at expanding CD8
+ T cells specific for the MART-1
melanoma antigen, is unlikely to have a major impact since the
population of MART-1-specific T cells expanded by the DC
vaccine is very small [30,40]. Another possibility is the difference
in dose of tremelimumab as three patients in the NRA
combination study received a lower dose of tremelimumab at
10 mg/kg. However, we did not detect evidence of tremelimu-
mab dose-response effects in these studies. Another source of
variability is the different timing of leukapheresis, with a median
of over 2 months from the first dose of tremelimumab in the
NRA study compared to approximately one month in the GA
study. However, pharmacokinetic analysis predict that serum
tremelimumab concentrations should be above 10 mg/ml up to
three months both in the 10 mg/kg and 15 mg/kg doses [10],
which is the minimum concentration of this antibody correlating
with a biological effect [9]. The fact that most results are evident
and concordant in both series, but more likely to be significant in
the larger GA sample set, turns us to believe that the difference in
the number of patients (6 compared to 21) may be the major
factor responsible for the differences in statistically significant
results.
Figure 4. Basal levels of TCR and cytokine signaling pathway activation in samples taken from patients in the GA study
administering single agent tremelimumab. PBMC obtained from patients before (Pre) and after (Post) single agent tremelimumab were
analyzed by phosphoflow as described in Figure 2 within each of the three cell subsets: CD4
+, CD8
+ (gated as CD3
+CD4
2) and CD14
+ cells. a) pLck
(pY505), b) pZAP70 (pY292), and c) pLAT (pY171) representative of proximal T Cell receptor (TCR) activation, only analyzed in CD3 subsets. d) pAKT
(pT308), e) pp38 (pT180/pY182) and f) pERK1/2 (T202/204) as intracellular signaling pathways downstream of surface receptors. g) Phospho-STAT1
(pY701), h) pSTA3 (pY705), i) pSTAT5 (Y694), and j) pSTAT6 (Y641) as a measure of cytokine receptor signaling. Statistically significant results are
denoted with asterisks as described in Figure 2.
doi:10.1371/journal.pone.0012711.g004
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the phosphorylation of the early TCR signaling molecules Lat, Lck
and Zap70 in the post-dosing samples of patients receiving
therapeutic CTLA4 blockade. Zap70 is a src kinases with a major
role in proximal TCR signaling, and it would have been expected
that upon CTLA4 blockade there should be enhanced signaling
from the TCR. In preclinical models it has been well established
that engagement of CTLA4 leads to decreased phosphorylation of
Lck and Zap70 [3], while CTLA4 knock out mice [14] and humans
with polymorphisms in CTLA4 that lead to decreased inhibitory
function [17], have constitutively increased phosphorylation in Lck
and Zap70. In addition, the GA series demonstrated significantly
decreased phosphorylation of Erk1/2 in post-dosing samples, a
finding that also goes against our expectations based on data from
preclinical models [18]. On the contrary, there was an increase in
phosphorylated p38, also a MAPK signaling molecule. Collectively,
these data suggest a decrease in most signaling molecules
downstream of the TCR after continuous CTLA4 blockade in
patients. An explanation would be that the time point of sampling
(between 1 and 2.5 months after administration of tremelimumab in
most cases) would detect late negative feedback loops triggered by
continuous pathway activation that lead to inhibition of upstream
phosphorylation or the activation of phosphatases [14], while
activation of p38 would continue to be evident.
There was a consistent modulation of STAT signaling after the
administration of tremelimumab. In all cell subsets and in both
series there was evidence of increase in pSTAT1 and pSTAT3,
with decrease in pSTAT5 and a non-significant but evident trend
of pSTAT6 decrease. The STAT pathway is not the first one that
comes to mind when thinking about downstream modulation after
CTLA4 blockade. However, given the known effects of CTLA4 in
altering cytokine production, in particular IL-2, and reports of
STATs being phosphorylated downstream of the MAPK and
Pi3K/Akt pathways [26,27,41,42], it is not surprising that
continuous antibody-mediated CTLA4 blockade would alter
cytokine levels and lead to changes in the signaling through
STATs [43]. In addition to the basal level analysis of STAT
phosphorylation, we stimulated pre- and post-dosing PBMC with
cytokines to determine if pre-dosing samples would be anergic and
post-tremelimumab treatment samples would have increased
Figure 5. Analysis of signaling patterns in samples from clinically responding and non-responding patients in the GA study
administering single agent tremelimumab. Phosphoflow results from patients before (Pre) and after (Post) single agent tremelimumab
separated among patients with a clinical response (R) or no response (NR). Samples were analyzed by phosphoflow as described in Figure 2. a and b)
pZAP70 (pY292) in CD4
+ and CD8
++ cell subsets. c, d and e) pAkt (pT308) in CD4
++, CD8
+ and CD14
+ cell subsets. f, g, and h) pSTAT6 (Y641) in all
three cell subsets. Statistically significant results are denoted with asterisks as described in Figure 2.
doi:10.1371/journal.pone.0012711.g005
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pre-treatment samples have the same ability as post-treatment
samples to signal upon cytokine stimulation. It has been previously
reported that PBMC from patients with melanoma have decreased
ability to respond to IFNs with an increase in pSTAT1 compared
to healthy controls [44]. The absence of a healthy donor control
group in our studies precluded us from being able to corroborate
these observations.
A major finding in our studies is the unexpected profound
alteration of signaling pathways in monocytes from patients
treated with tremelimumab. In fact, post-dosing increases in
phosphorylated p38, STAT1 and STAT3 in monocytes were the
most consistent findings when comparing results from both
datasets. These results point us to speculate that monocytes, a
cell subset with known CTLA4 expression [8], may be a major
and previously unrecognized player in the antitumor activity of
anti-CTLA4-based therapy. We confirmed that monocytes do
express CTLA4 but this is mostly intracellular. Direct engagement
of CTLA4 on monocytes upon increasing concentrations of
tremelimumab in vitro yielded minor changes on signaling
phosphoproteins in monocytes, some of which were congruent
with the findings in monocytes obtained from peripheral blood of
patients treated with tremelimumab. This suggests to us that some
of the effects we detected in monocytes may be a combination of
direct modulation of CTLA4 on monocytes as well as indirectly
due to changes in cytokine levels upon CTLA4 blockade in
neighboring T cells. Interestingly, anti-TNF-a-based treatments
are recognized as the most powerful immune suppressive
treatment for the reversal of autoimmune toxicities induced by
CTLA4 antibodies [45,46]. Since monocytes are high producers of
TNF-a, our observation of modulation of monocyte intracellular
signaling may provide an explanation for the clinical activity of
agents like infliximab.
In the exploratory analysis comparing peripheral blood samples
from patients with and without a clinical response, we noted that
three signaling molecules had a different pattern of change in
samples from clinical responders. It is rather surprising to us that
these changes were a decreased phosphorylation of the proximal
TCR signaling molecules Zap70 and LAT, with concordant
decrease in pAkt and pSTAT6. Samples from non-responding
patients had either no change in the phosphorylation of these same
signaling molecules, or an opposing increasing trend. The
significance of these changes is unclear at this time and will
require further validation in larger sets of patients with larger
numbers of clinical responders. However, it is of interest to note
that STAT6 has been described as a signaling molecule
downstream of Akt [41,42], suggesting to us that these changes
after receiving tremelimumab may be reflective of a specific
pathway modulation leading to more effective tumor targeting and
killing.
In conclusion, tremelimumab-based therapy in patients with
melanoma results in alterations of signaling pathways downstream
of the TCR and cytokine receptors. This work provides a clear
evidence of pharmacodynamic effects consistent with the suspect-
ed mechanism of action of CTLA4 blocking antibodies. Modu-
lation of p38 and STATs was most prominent in CD14
+
monocytes, suggesting that further studies focusing on the
contribution of monocytes and differentiated macrophages or
myeloid DCs may shed more light on the mechanism of action of
CTLA4 blocking monoclonal antibodies. In addition, studying
patterns of different phosphorylated signaling molecules in patients
with or without clinical response may allow defining if clinical
benefit is guided by a different modulation of the immune system
by CTLA4 blocking antibodies.
Supporting Information
Table S1 *Beckman Coulter and Invitrogen**, eBioscience***;
the other antibodies from BD Biosciences; Ax= AlexaFluor; PE=
Phycoerythrin; APC= Allophycocyanin; Cy= cyanine; PE-
pSTAT6 (pY641; clone 18).
Found at: doi:10.1371/journal.pone.0012711.s001 (0.04 MB
DOC)
Table S2 *Beckman Coulter and Invitrogen**; the other
antibodies from BD Biosciences; Ax= AlexaFluor; PE= Phyco-
erythrin; APC= Allophycocyanin; Cy= cyanine. All of the
antibodies were the clones described in Table S1.
Found at: doi:10.1371/journal.pone.0012711.s002 (0.04 MB
DOC)
Table S3 Time course for activation TCR signaling in fold
change from baseline.
Found at: doi:10.1371/journal.pone.0012711.s003 (0.04 MB
DOC)
Figure S1 Effects of cell fixation and permeabilization on the
detection of surface staining for immune cell markers. Flow
cytometric identification of CD3 (UCHT1), CD4 (RPA-T4),
CD14 (Tu ¨K4), and CD8 (OKT8) populations by antibody
staining in fixed and permeabilized human PBMC. PBMC from
patients with advanced melanoma were kept alive or fixed with
2% paraformaldehyde (PFA) and permeabilized with 90%
methanol (MeOH) before staining with the respective antibodies.
CD8 (RPA-T8) staining could not be identified by flow cytometry
after 2% paraformaldehyde/90% methanol treatment.
Found at: doi:10.1371/journal.pone.0012711.s004 (3.82 MB TIF)
Figure S2 Titration of cytokines in healthy donor PBMC. a)
Formula for the calculation of the geometric series. Max:
maximum value of the curve, a= min: minimum value of the
curve, n: numbers of points in the curve. b) Dose-response curve
for IFN- alpha [readout was pSTAT1 (pY701) and pSTAT5
(pY694)]; IFN-gamma [readout pSTAT1(pY701)]; IL-2, IL-7 and
IL-15 [pSTAT5 (pY694)]; IL-6 [pSTAT3 (pY705)]; IL-4
[pSTAT6(pY641)]. c) Final concentration of saturating levels of
cytokines used in this study were selected from the plateau of the
curve.
Found at: doi:10.1371/journal.pone.0012711.s005 (1.81 MB TIF)
Figure S3 Effects of IFN-alpha cytokine stimulation on
phosphorylated STAT1 and STAT5 in samples taken from
patients in the combined therapy NRA study. PBMC obtained
from patients before (Pre) and after (Post) receiving tremelimumab
together with MART-126-35 peptide pulsed dendritic cells (DC)
were stimulated with 10,000 IU/ml of IFN-alpha for 15 minutes
(S) and compared to unstimulated samples (U). Labeled cells were
analyzed by phosphoflow for pSTAT1 (pY701, top row) or
pSTAT5 (Y694, bottom row) as described in Figure 2. a and d)
CD4+ CD3+ T helper cells. b and e) CD4-CD3+ cytotoxic T
lymphocytes (CTLs). c and f) CD14+ monocytes. Statistically
significant results are denoted with asterisks as described in
Figure 2.
Found at: doi:10.1371/journal.pone.0012711.s006 (0.74 MB TIF)
Figure S4 Effects of gamma chain receptor-mediated cytokine
stimulation with IL-2, IL-7 and IL-15 on phosphorylated STAT5
in samples taken from patients in the combined therapy NRA
study. PBMC obtained from patients before (Pre) and after (Post)
tremelimumab together with MART-126-35 peptide pulsed
dendritic cells (DC) were stimulated with 400 IU/ml of IL-2 (top
row), 20 ng/ml of IL-7 (middle row) or 50 ng/ml of IL-15 (bottom
row) for 15 minutes (S), and compared to unstimulated samples
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PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e12711(U). Labeled cells were analyzed by phosphoflow for pSTAT5
(Y694) as described in Figure 2. a, d and g) CD4+CD3+ T helper
cells. b, e and h) CD4-CD3+ cytotoxic T lymphocytes (CTLs). c, f
and i) CD14+ monocytes. Statistically significant results are
denoted with asterisks as described in Figure 2.
Found at: doi:10.1371/journal.pone.0012711.s007 (2.22 MB TIF)
Figure S5 In vitro monocyte experiments. a) Representative
results of extracellular and intracellular CTLA4 expression in
monocytes. After gating monocytes by morphology, single cells
were gated as CD14+CD3-. b) Gating strategy for phosphoryla-
tion experiments. After gating on monocytes by morphology,
single cells were gated as CD14+CD3-. Six populations of cells,
each one exposed to a different concentration of tremelimumab
for 48 hours, were analyzed simultaneously based on fluorescent
dye barcoding with Ax350-NHS and Ax-750-NHS. Each one of
the differently labeled groups represents cells treated with
increasing concentrations of tremelimumab in which intracellular
phosphoproteins were analyzed by mean fluorescence intensity
(MFI).
Found at: doi:10.1371/journal.pone.0012711.s008 (2.32 MB TIF)
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